Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:05 AM
Ignite Modification Date:
2025-12-25 @ 1:05 AM
NCT ID:
NCT07226193
Brief Summary:
1\) The purpose of this study is to assess segmental pulse arrival time (PAT) as an alternative biomarker to detect lower-extremity peripheral artery disease (PAD). The secondary purpose will be to investigate the impacts of age on segmental PAT. The subject population will include any adults 19 years of age or older with or without PAD. Exclusion criteria include having an aortic aneurysm with or without previous intervention, previous revascularization surgeries of the arteries in the legs/aorta, walking impairments independent of PAD, gangrene or ulcers of the toes/feet, and currently pregnant or breastfeeding. 3) All aims of the present study will be completed with a single laboratory visit. Descriptive measurements will include height, weight, age, sex, body fat percentage, and self-reported medication and health history. Subjects will lie in the supine position for 20-min. After rest, either the ankle-brachial index (ABI) or PAT will be assessed. After 10-min of further rest, the other measurement will be performed. ABIs will be assessed according to current guidelines: blood pressures will be assessed in the dorsal pedis and tibialis posterior arteries of both legs and the brachial arteries of both arms using a blood pressure cuff and Doppler ultrasound. PAT will be simultaneously assessed in both arms and legs using an investigational device with a 3-lead electrocardiogram sensor and four photoplethysmography (PPG) sensors. A PPG sensor will be applied to both middle fingers and both big toes. Signals will be collected for 15-min. Thermal images of the fingers and toes will be assessed before and after using the investigational device. After assessment of ABI and PAT, subjects will participate in a 6-min walking test (6MWT) to objectively establish walking capacity. The 6MWT will be performed in accordance with current guidelines. Cones will be separated by 30 meters on a straight flat walkway. Subjects will be instructed to walk back and forth between the cones as fast as they can for 6-min. Subjects will be allowed to rest during the test, if necessary, but the stopwatch will continue to run. Segmental PATs will be compared with ABI and 6-min walking time to determine if segmental PATs can predict lower-extremity PAD (ABI) and the associated walking impairment (6MWT). This study is expected to last \~2hrs. 4) There will be no follow-up.
Detailed Description:
Specific Aim 1: Determine if segmental pulse arrival times can predict lower-extremity peripheral artery disease assessed with ankle-brachial index and the 6-min walking test.
Specific Aim 2: Determine the effects of age on segmental pulse arrival times.
After the process of informed consent, descriptive measurements will be assessed. Descriptive measures include height, weight, body composition, age, and sex. Height and weight will be assessed with a standard stadiometer and scale, respectively. Body composition will be assessed non-invasively with bio-electric impedance analysis (Omron HBF-306C Handheld Scanner, OMRON Healthcare, Kyoto, Japan). Bioelectric impedance devices send a small electric current through the body and estimates body fat percentage based on the impedance to electrical flow through the body segments. Our bio-electric impedance device creates a circuit between the hands and feet of the subject to estimate body fat percentage. The electric current used in bioelectric impedance devices is very small and cannot be felt by the participant. Subjects will also self-report their medication and health history.
After the assessment of descriptive measurements, subjects will rest in the supine position for 20-min. After 20-min of rest, the subjects will have either ankle-brachial index (ABI) or segmental pulse arrival times (PATs) assessed. After a 10-min period of rest, the other measurement will be assessed (either ABI or PAT). The order of ABI and PAT will be randomized, and all subjects will have ABI and PAT assessed.
1a) Assessment of PAT with the Investigational Device: The subjects will be instrumented with an investigational device comprised of an array of four photoplethysmography (PPG) sensors and one 3-lead electrocardiogram (ECG) sensor. Electrocardiogram is a non-invasive technique that is used to monitor the electrical dipoles generated by membrane potentials within the myocardium and electrical conduction systems of the heart. PPG is a non-invasive technique to assess hemoglobin content within the microcirculation of the skin. Our PPG sensors are applied superficially on the skin and shines continuous-intensity green light into the skin (580 nm). The green light is absorbed by hemoglobin. Therefore, by the modified Beer-Lambert principle, the amount of light reflected back to the PPG unit gives an index of hemoglobin content within the microvasculature. The PPG and ECG sensors are integrated into a microcontroller (small computer), which reads the voltages of the sensors and displays the data in real time in a custom computer software. Each PPG sensor will have a skin-safe double-sided adhesive attached to the sensor housing. Two PPG sensors will be adhered to both middle fingers on the palmar side of the hands. Two PPG sensors will be adhered to the plantar aspect of both big toes. Altogether, there will be one PPG sensor per hand and one PPG sensor per foot. The ECG sensor will be applied to form limb leads: one electrode per wrist on the ventral aspect of the forearm and one electrode on a hair-free portion of the left leg. If an adequate ECG signal is not obtained using limb leads, then chest leads will be utilized. In this configuration, electrodes will be placed inferior to the left and right clavicle, and medial to the shoulders, and one electrode will be placed on the left lateral aspect of the ribcage near the apex of the heart. Once all sensors have been placed, the subject will rest for 15-min in the supine position, and all signals will be collected continuously. PAT will be calculated for each arm and each leg as the difference in time between the R-wave appearing in the ECG signal and the pulse wave appearing in the distal PPG signals. All four PAT values will be used to develop a composite score to estimate the presence of lower-extremity PAD. Leg asymmetry will be assessed with the ratio of PATs from left and right legs. Atherosclerotic plaque-mediated pulse wave slowing will be assessed as the ratio of PATs in the arms compared to the legs. The product of these ratios forms the composite score to detect lower-extremity PAD, which is sensitive to both 1) asymmetry in PATs in the legs (may indicate unilateral lower-extremity PAD) and 2) longer PATs in the legs compared to the arms (may indicate the presence of lower-extremity PAD).
1b) Thermal Imaging: Immediately prior to applying and immediately after removing the PPG sensors, a thermal imaging camera (FLIR T540) will be used to take a thermal image of the skin where the PPG sensors will be/were applied. The purpose of using the thermal camera is to document the local skin temperature before and after using the investigational device. The thermal camera will automatically select the warmest region of the image and document the temperature. Of note, the thermal imaging camera will be zoomed in on the fingers and toes where the PPG sensors were located, and no identifiable body parts (e.g., face) or clusters of body parts (e.g., zoomed out images) will be included in the thermal images. Therefore, the risk of identifying subjects with the thermal images will be minimized.
2\) Assessment of ABI: ABI will be assessed according to current guidelines established by the American Heart Association and the American College of Cardiology. Blood pressures will be assessed in both legs and in both arms. For all blood pressure assessments, the blood pressure cuff will be manually inflated to a supra-systolic pressure. During slow manual cuff deflation, a Doppler ultrasound (non-invasive) will be used to listen for the first Korotkoff sound, which is the systolic blood pressure. Using this procedure, the systolic blood pressure will be quantified for both the ipsilateral dorsalis pedis and posterior tibial arteries for both legs. Furthermore, systolic blood pressure will be assessed in the brachial arteries of both arms. ABI will be quantified as the ratio of the higher systolic blood pressure in the legs divided by the higher systolic blood pressure in the arms.
3\) 6-minute walking test: After the assessments of ABI and PAT, subjects will participate in a 6-min walking test to objectively quantify exercise capacity. Two cones will be separated by 30 m on a straight and flat walkway. Subjects will be instructed to walk back and forth between the cones as fast as they can for 6-min to achieve the farthest distance that they can. Subjects will be allowed to rest during the test, but the stopwatch time will not be stopped. All components of the test will be explained clearly prior to performing the test. Comprehension of the objectives of the test will be confirmed prior to initiating the test. Prior to performing the 6-min walking test, blood pressure, heart rate, and the rating of perceived exertion (RPE) will be recorded in the seated position. Furthermore, blood pressure, heart rate, and RPE will be recorded with the subject in the seated position immediately after exercise and every 5-min thereafter until the pre-exercise heart rate and blood pressure are re-established (w/in +/-5 beats and +/-5 mmHg) in alignment with American College of Sports Medicine guidelines.
The study duration is expected to be \~2 hrs, and there will be no follow-up.
Study:
NCT07226193
Study Brief:
Protocol Section:
NCT07226193